Inspected site(s):	Name and full address of the Inspected site
Activities Carried out	Manufacture of Active SubstanceManufacture of Finished Medicinal ProductPackagingImportingLaboratory TestingBatch Control and Batch Release
Inspection date(s):	Date(s), month, year
Inspector(s):	Name of the inspector(s),
	Name of expert / assessor (if applicable)
	Name of the Competent Authority(ies).
References:	Number of Marketing and / or Manufacturing Authorisations
	EMEA reference number(s).( If the inspection is an EMEA inspection)
Introduction:	Short description of the company and the activities of the company.
	It should be noted if a site master file was available before the inspection. Date of the site master file.
	<u>For inspections in non-EC/EEA countries</u> it should be stated whether the Competent Authority of the country, where the inspection took place, was informed of the inspection and whether the Competent Authority took part in the inspection.
	Date of previous inspection
	Names of Inspectors involved in previous inspection
	Major changes since the previous inspections should be detailed.

## GMP Inspection report - Community format

Brief report of the inspection activities undertaken:		
Scope of Inspection:	Short description of the inspection (Product related inspection and/or General GMP inspection). The reason for the inspection should be specified.	
Inspected area(s):	Each inspected area should be specified.	
Personnel met during the inspection:	The names and titles of key personnel met, should be specified,( listed in annex)	
Inspectors Team's findings and observations:	Relevant headings from The Rules Governing Medicinal Products in the European Community, Good Manufacturing Practice for Medicinal Products Vol. IV. New headings may be introduced when relevant.	
Headings to be used ( Choose those headings relevant to the scope of the Inspection):	Quality Management	
	Personnel	
	Premises and Equipment	
	Documentation	
	Production	
	Quality Control	
	Contract Manufacture and Analysis	
	Complaints and Product Recall	
	Self Inspection	
	Questions from the Assessment of the Application ( Pre- authorisation Inspections)	
	Investigation of Product Recall or Product Defect	
Miscellaneous:		
Samples taken		
Distribution		
Assessment of the Site Master File		
Annexes attached:	List of any annexes attached	

Summary of Deficiencies:	The deficiencies should be listed and the relevant reference to the EU GMP Guide and other relevant EU Guidelines should be mentioned.
	If the deficiencies are related more to the assessment of the application it should be clearly stated.
	The company should be asked to inform the Inspectorate about the progress of the corrected actions and a proposed time schedule for corrections.
Recommendations	To the Committee requesting the Inspection or to the Management / Enforcement Authority for the site inspected
Summary and conclusions:	The Inspection Team should state if the Company operates in accordance with the EU GMP Rules.
Name(s)	The Inspection Report should be signed and dated by the Inspector(s)/Assessors having participated
Signatures(s)	in the Inspection.
Organisation(s)	
Date:	

г

-

## **Definition** of Significant Deficiencies

- 1. CRITICAL DEFICIENCY: A deficiency which has produced, or leads to a significant risk of producing either a product which is harmful to the human or veterinary patient or a product which could result in a harmful residue in a food producing animal.
- 2. OTHER SIGNIFICANT DEFICIENCY: A non-critical deficiency, which has produced or may produce a product, which does not comply with its marketing authorisation.
- or which indicates a significant deviation from EU Good Manufacturing Practice.
- *or* (within EU) which indicates a significant deviation from the terms of the manufacturing authorisation.

*or* which indicates a failure to carry out satisfactory procedures for release of batches or (within EU)

a failure of the Qualified Person to fulfil his legal duties.

**Note:** Several smaller related deficiencies, none of which on their own may be significant, may together represent a significant deficiency and should be reported as such